Literature DB >> 22942888

Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review.

Vitaly Golub1, Prashant Malhotra, Shital Patel.   

Abstract

Bacille Calmette-Guérin (BCG) immunotherapy is widely used for the treatment of superficial bladder cancer. The authors believe that the present report is one of the first to document cerebral BCG tuberculoma in a 73-year-old immunocompetent man, three years after intra-vesical BCG immunotherapy. His workup revealed no identifiable extracranial source. He responded well to treatment with rifampin, ethambutol and moxifloxacin.Patients undergoing intravesical BCG therapy should be closely monitored for the development of this complication. Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections.

Entities:  

Keywords:  BCG; Bladder cancer; Cerebral; Tuberculoma

Year:  2011        PMID: 22942888      PMCID: PMC3200374          DOI: 10.1155/2011/869286

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  17 in total

1.  Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child.

Authors:  M J Coppes; N F Olivieri; M Howes; M Pusic; R Gold; S E Richardson
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

Review 2.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

3.  A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France.

Authors:  J Robert; F Boulahbal; D Trystram; C Truffot-Pernot; A C de Benoist; V Vincent; V Jarlier; J Grosset
Journal:  Int J Tuberc Lung Dis       Date:  1999-08       Impact factor: 2.373

4.  Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

Authors:  H M J Nijland; R Ruslami; A Juwono Suroto; D M Burger; B Alisjahbana; R van Crevel; R E Aarnoutse
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

5.  Fatal BCG infection in an immunocompetent girl.

Authors:  F K Pedersen; H C Engbaek; H Hertz; B Vergmann
Journal:  Acta Paediatr Scand       Date:  1978-07

6.  Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.

Authors:  J W C Alffenaar; R van Altena; H J Bökkerink; G J Luijckx; D van Soolingen; R E Aarnoutse; T S van der Werf
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

7.  Cerebral tuberculosis in the immunocompetent host: 8 cases observed in Switzerland.

Authors:  N Labhard; L Nicod; J P Zellweger
Journal:  Tuber Lung Dis       Date:  1994-12

8.  Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children.

Authors:  Anneke C Hesseling; Hendrik S Schaaf; Thomas Victor; Nulda Beyers; Ben J Marais; Mark F Cotton; Ian Wiid; Robert P Gie; Paul van Helden; Robin M Warren
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

9.  Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005.

Authors:  Michele C Hlavsa; Patrick K Moonan; Lauren S Cowan; Thomas R Navin; J Steve Kammerer; Glenn P Morlock; Jack T Crawford; Philip A Lobue
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

10.  Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis.

Authors:  Linda M Parsons; Roland Brosch; Stewart T Cole; Akos Somoskövi; Arthur Loder; Gisela Bretzel; Dick Van Soolingen; Yvonne M Hale; Max Salfinger
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.